Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with ...
CRPS-RISE designed to support FDA regulatory submission for potential approval of neridronate in patients with CRPS-1 FDA has previously granted neridronate with Breakthrough Therapy, Fast Track, and Orphan Drug designations IRVINE, Calif., June 08, 2026 ( …